Ord Minnett Sticks to Its Buy Rating for Brazilian Rare Earths Ltd. (BRE)
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Hope is a 4-star analyst with an average return of 9.5% and a 53.93% success rate. Hope covers the Basic Materials sector, focusing on stocks such as Boss Energy , Lynas Rare Earths , and ioneer Limited.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Brazilian Rare Earths Ltd. with a A$5.48 average price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Boralex Inc Cl A (BLX) was downgraded to a Hold Rating at Scotiabank
Boralex Inc Cl A received a Hold rating and a C$36.00 price target from Scotiabank analyst Robert Hope today. The company's shares opened today at C$31.50. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Hope is a 5-star analyst with an average return of 11.1% and a 68.01% success rate. Hope covers the Utilities sector, focusing on stocks such as Brookfield Infrastructure, Brookfield Renewable Partners, and Algonquin Power & Utilities. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boralex Inc Cl A with a C$40.33 average price target.
Business Insider
3 days ago
- Business Insider
Ord Minnett Sticks to Its Buy Rating for BlueBet Holdings Ltd. (BBT)
In a report released today, Phillip Chippindale from Ord Minnett maintained a Buy rating on BlueBet Holdings Ltd., with a price target of A$0.46. The company's shares opened today at A$0.31. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Chippindale is an analyst with an average return of -0.8% and a 39.01% success rate. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BlueBet Holdings Ltd. with a A$0.47 average price target.
Business Wire
3 days ago
- Business Wire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ('Capricor' or 'the Company') (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 9, 2024, and July 10, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before September 15, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Capricor touted its successful movement towards FDA approval for its deramiocel drug candidate, such as a mid-cycle review with no important deficiencies and the planning of an advisory committee meeting. Despite this positivity, the Company was concealing adverse data from the Phase 2 HOPE-2 trial. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
